Lotessa takes GLP-1 aftercare app to US at HLTH 2026
Nexus-based founder Tsitsi Chinyandura is seeking US licensing deals and investment for her GLP-1 aftercare app after its first showing in the US.

Lotessa, the Leeds GLP-1 app built by patient-founder Tsitsi Chinyandura, has taken its first step into the US market at HLTH USA 2026, held in Las Vegas from 15 to 18 November. Lotessa Digital Health, which is based at Nexus at the University of Leeds, is seeking licensing agreements with US telehealth providers and weight-loss clinics, along with investment to support its US launch.
How the Leeds GLP-1 app works for providers
Tsitsi Chinyandura started GLP-1 treatment in 2024. She found getting a prescription straightforward but managing the day-to-day experience harder, as side effects, appetite changes and questions about nutrition carried on between prescriptions. She founded the company in 2025 and launched the app in the UK in August.
Patients use the Leeds GLP-1 app to log doses, side effects and nutrition, complete a daily check-in and join a peer community. Providers license it for the people they support, either co-branded or under their own brand. They see engagement data through a provider dashboard. The app can already be downloaded in the US on the App Store and Google Play. In the UK it holds ORCHA Assured (Bronze) status following an independent assessment.
Gallup found that 11% of US adults were taking a GLP-1 for weight loss in 2026, up from 3% in 2024. Few stay the course: research published in 2025 by US pharmacy benefit manager Prime Therapeutics found only 1 in 12 commercially insured adults who began a GLP-1 for obesity were still taking it three years later.
“At HLTH, US providers described the same challenge we see in the UK: getting people started on a GLP-1 is the easy part, but supporting them between prescriptions is harder,” said Tsitsi Chinyandura, founder of Lotessa Digital Health. “When people stop treatment early, they lose support, and providers lose the relationship.”
“Aftercare has become a commercial question as well as a clinical one, and that is the conversation we came to the US to have.”
Tsitsi Chinyandura, Founder, Lotessa Digital Health
A route into the US through Nashville
In August 2026, with support from Nexus, Lotessa was one of the start-ups showcased at Health Innovation Without Borders, a virtual event run by the Nashville Entrepreneur Center and Nexus on healthcare innovation and transatlantic links between the two cities. At HLTH, Tsitsi met the centre’s team in person for the first time. Lotessa plans to work with the centre, a non-profit that supports Nashville founders including healthcare start-ups, as it enters the US.
Nashville is home to the headquarters of 17 publicly traded healthcare companies. The Nashville Health Care Council puts healthcare’s contribution to the area’s economy at $72.1bn a year. The link adds to other routes into the US for the region’s health innovators, such as Health Innovation Yorkshire and Humber’s partnership with St Louis.
Lotessa describes itself as a wellbeing app that does not replace advice from a prescriber.
Sources: Gallup, In U.S., GLP-1 Usage Reaches New High, 7 July 2026; Prime Therapeutics announcement, 25 June 2025
- Expansion / new marketLotessa takes GLP-1 aftercare app to US at HLTH 2026
- Expansion / new market




